The Tristel share price crashes on a profit warning: should I buy?

The Tristel share price is crashing after the medical disinfectant specialist warned of a big fall in profits due to the impact of Covid-19.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Tristel (LSE: TSTL) share price crashed when markets opened on Monday. The fall came after the medical disinfectant specialist warned that 2021 profits will be lower than expected.

Tristel shares are down by 17%, as I write, leaving them 12% higher than one year ago. Even so, this stock remains an impressive winner on a longer-term view, up 375% in five years. I’m wondering whether the big gains are in the past, or whether today’s drop could be an opportunity for me to buy into Tristel.

What’s gone wrong?

Tristel has two main product lines. It makes surface disinfectant products and medical device disinfectants. Both use the company’s proprietary chlorine dioxide chemistry. The NHS is Tristel’s largest customer.

Over the last year, the Covid-19 pandemic has driven a sharp increase in sales of surface disinfectant products. The problem is that sales of Tristel’s medical device disinfectants have slumped.

The pandemic has forced the NHS to delay/cancel thousands of procedures in areas such as urology, ENT, cardiology, and gynaecology. Tristel’s products are used to disinfectant the devices commonly used in such examinations. This means demand has been much lower than usual.

Tristel’s management now expect pre-tax profit for the year to 30 June to be “not less than £5m.” This is a big miss on broker forecasts I’ve seen of £7m, hence Tristel’s share price fall today.

Is it as bad as it looks?

In its first-half results in February, Tristel said that sales of device disinfectants were suffering because of the impact of Covid-19. Even so, the company generated a pre-tax profit of £3.1m during the first half.

However, it seems like half-year sales may have been boosted by Brexit stockpiling. This is now unwinding. Today’s news suggests the firm’s profits are expected to fall to around £2m during the second half.

I think it’s worth remembering that even after Covid-19-related growth, surface disinfectants are still a relatively small part of Tristel’s business. During the six months to 31 December, surface disinfectant sales totalled £2m, compared to £13.1m for medical device disinfectants.

Costs are also rising sharply. According to management, Tristel’s cost base has risen by 6% (£0.8m) over the last year, as the business has recruited new staff to support expansion.

This increase in costs represents 11% of last year’s pre-tax profit. With Covid-19 putting pressure on sales of the company’s main product range, I’m not entirely surprised by today’s profit warning.

Tristel share price: watching brief

In general, I think Tristel is a good business with long-term growth potential. If the company can finally gain regulatory approval in the US, sales growth could accelerate. However, the company’s attempt to expand in the US has been ongoing for years, with no success so far. It’s been expensive too — Tristel spent £750,000 generating scientific data for US regulators last year.

Tristel shares looked expensive to me before today’s profit warning, and that hasn’t changed. At around 550p, I estimate the shares could still be trading on about 60 times 2021 forecast earnings.

In fairness, I think Tristel should deliver a strong recovery in 2021/22. But the stock’s strong valuation doesn’t seem to provide much margin for error. I’m not comfortable buying at current levels.

This is a story I’ll continue to watch from the sidelines.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »